
<document id="DBMI.pac188" origId="pac188">
	<sentence id="DBMI.pac188.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nAtazanavir is an antiviral drug [see Clinical Pharmacology (12.4)]."/>
	<sentence id="DBMI.pac188.s1" origId="s1" text="12.2 Pharmacodynamics\n\nEffects on Electrocardiogram\n\nConcentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir."/>
	<sentence id="DBMI.pac188.s2" origId="s2" text="In a placebo-controlled study (AI424-076), the mean (SD) maximum change in PR interval from the predose value was 24 (15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (11) msec following dosing with placebo (n=67)."/>
	<sentence id="DBMI.pac188.s3" origId="s3" text="The PR interval prolongations in this study were asymptomatic."/>
	<sentence id="DBMI.pac188.s4" origId="s4" text="There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram."/>
	<sentence id="DBMI.pac188.s5" origId="s5" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s6" origId="s6" text="Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects."/>
	<sentence id="DBMI.pac188.s7" origId="s7" text="Oral doses of 400 mg and 800 mg were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericias correction)."/>
	<sentence id="DBMI.pac188.s8" origId="s8" text="In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens."/>
	<sentence id="DBMI.pac188.s9" origId="s9" text="No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval &gt;500 msec."/>
	<sentence id="DBMI.pac188.s10" origId="s10" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s11" origId="s11" text="In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.">
		<entity charOffset="1469-1480" id="DBMI.pac188.s11.e0" origId="s11.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1502-1512" id="DBMI.pac188.s11.e1" origId="s11.e1" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac188.s11.e0" e2="DBMI.pac188.s11.e1" id="DBMI.pac188.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diltiazem " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.s11.e1" e2="DBMI.pac188.s11.e0" id="DBMI.pac188.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac188.s12" origId="s12" text="In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval.">
		<entity charOffset="1694-1705" id="DBMI.pac188.s12.e0" origId="s12.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1727-1736" id="DBMI.pac188.s12.e1" origId="s12.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac188.s12.e0" e2="DBMI.pac188.s12.e1" id="DBMI.pac188.s12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.s12.e1" e2="DBMI.pac188.s12.e0" id="DBMI.pac188.s12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac188.s13" origId="s13" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac188.s14" origId="s14" text="12.3 Pharmacokinetics\n\nThe pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with ritonavir 100 mg once daily (see Table 14)."/>
	<sentence id="DBMI.pac188.s15" origId="s15" text="Figure 1 displays the mean plasma concentrations of atazanavir at steady state after REYATAZ 400 mg once daily (as two 200-mg capsules) with a light meal and after REYATAZ 300 mg (as two 150-mg capsules) with ritonavir 100 mg once daily with a light meal in HIV-infected adult patients."/>
	<sentence id="DBMI.pac188.s16" origId="s16" text="Absorption\n\nAtazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours."/>
	<sentence id="DBMI.pac188.s17" origId="s17" text="Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200800 mg once daily."/>
	<sentence id="DBMI.pac188.s18" origId="s18" text="Steady-state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold."/>
	<sentence id="DBMI.pac188.s19" origId="s19" text="Food Effect\n\nAdministration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability."/>
	<sentence id="DBMI.pac188.s20" origId="s20" text="Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state."/>
	<sentence id="DBMI.pac188.s21" origId="s21" text="Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state."/>
	<sentence id="DBMI.pac188.s22" origId="s22" text="Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state."/>
	<sentence id="DBMI.pac188.s23" origId="s23" text="Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state."/>
	<sentence id="DBMI.pac188.s24" origId="s24" text="Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values."/>
	<sentence id="DBMI.pac188.s25" origId="s25" text="The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours."/>
	<sentence id="DBMI.pac188.s26" origId="s26" text="Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state."/>
	<sentence id="DBMI.pac188.s27" origId="s27" text="Distribution\n\nAtazanavir is 86% bound to human serum proteins and protein binding is independent of concentration."/>
	<sentence id="DBMI.pac188.s28" origId="s28" text="Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively)."/>
	<sentence id="DBMI.pac188.s29" origId="s29" text="In a multiple-dose study in HIV-infected patients dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen."/>
	<sentence id="DBMI.pac188.s30" origId="s30" text="The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42."/>
	<sentence id="DBMI.pac188.s31" origId="s31" text="Metabolism\n\nAtazanavir is extensively metabolized in humans."/>
	<sentence id="DBMI.pac188.s32" origId="s32" text="The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation."/>
	<sentence id="DBMI.pac188.s33" origId="s33" text="Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation."/>
	<sentence id="DBMI.pac188.s34" origId="s34" text="Two minor metabolites of atazanavir in plasma have been characterized."/>
	<sentence id="DBMI.pac188.s35" origId="s35" text="Neither metabolite demonstrated in vitro antiviral activity."/>
	<sentence id="DBMI.pac188.s36" origId="s36" text="In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A."/>
	<sentence id="DBMI.pac188.s37" origId="s37" text="Elimination\n\nFollowing a single 400-mg dose of 14C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively."/>
	<sentence id="DBMI.pac188.s38" origId="s38" text="Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively."/>
	<sentence id="DBMI.pac188.s39" origId="s39" text="The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal."/>
	<sentence id="DBMI.pac188.s40" origId="s40" text="Special Populations\n\nPediatrics\n\nThe pharmacokinetic data from pediatric patients receiving REYATAZ Capsules with ritonavir based on body surface area are presented in Table 15."/>
	<sentence id="DBMI.pac188.s41" origId="s41" text="Drug Interaction Data\n\nAtazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 M. Atazanavir is also a direct inhibitor for UGT1A1 (Ki=1.9 M) and CYP2C8 (Ki=2.1 M)."/>
	<sentence id="DBMI.pac188.s42" origId="s42" text="Atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A."/>
	<sentence id="DBMI.pac188.s43" origId="s43" text="In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous 6-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced."/>
	<sentence id="DBMI.pac188.s44" origId="s44" text="Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions."/>
	<sentence id="DBMI.pac188.s45" origId="s45" text="The effects of coadministration of REYATAZ on the AUC, Cmax, and Cmin are summarized in Tables 16 and 17."/>
	<sentence id="DBMI.pac188.s46" origId="s46" text="For information regarding clinical recommendations, see Drug Interactions (7)."/>
	<sentence id="DBMI.pac188.s47" origId="s47" text="12.4 Microbiology\n\nMechanism of Action\n\nAtazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI)."/>
	<sentence id="DBMI.pac188.s48" origId="s48" text="The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions."/>
	<sentence id="DBMI.pac188.s49" origId="s49" text="Antiviral Activity in Cell Culture\n\nAtazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC50) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells."/>
	<sentence id="DBMI.pac188.s50" origId="s50" text="ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture."/>
	<sentence id="DBMI.pac188.s51" origId="s51" text="ATV has variable activity against HIV-2 isolates (1.9 to 32 nM), with EC50 values above the EC50 values of failure isolates."/>
	<sentence id="DBMI.pac188.s52" origId="s52" text="Two-drug combination antiviral activity studies with ATV showed no antagonism in cell culture with NNRTIs (delavirdine, efavirenz, and nevirapine), PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity."/>
	<sentence id="DBMI.pac188.s53" origId="s53" text="Resistance\n\nIn Cell Culture: HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV)."/>
	<sentence id="DBMI.pac188.s54" origId="s54" text="HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral strains were selected in cell culture by 5 months."/>
	<sentence id="DBMI.pac188.s55" origId="s55" text="The substitutions in these HIV-1 viruses that contributed to ATV resistance include I50L, N88S, I84V, A71V, and M46I."/>
	<sentence id="DBMI.pac188.s56" origId="s56" text="Changes were also observed at the protease cleavage sites following drug selection."/>
	<sentence id="DBMI.pac188.s57" origId="s57" text="Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir)."/>
	<sentence id="DBMI.pac188.s58" origId="s58" text="The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively, and did not appear to be cross-resistant."/>
	<sentence id="DBMI.pac188.s59" origId="s59" text="Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients."/>
	<sentence id="DBMI.pac188.s60" origId="s60" text="A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 18."/>
	<sentence id="DBMI.pac188.s61" origId="s61" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg With Ritonavir 100 mg: In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA 400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment."/>
	<sentence id="DBMI.pac188.s62" origId="s62" text="In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M."/>
	<sentence id="DBMI.pac188.s63" origId="s63" text="The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance."/>
	<sentence id="DBMI.pac188.s64" origId="s64" text="Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline."/>
	<sentence id="DBMI.pac188.s65" origId="s65" text="The 150L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibiity from baseline."/>
	<sentence id="DBMI.pac188.s66" origId="s66" text="Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance."/>
	<sentence id="DBMI.pac188.s67" origId="s67" text="In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M."/>
	<sentence id="DBMI.pac188.s68" origId="s68" text="Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance."/>
	<sentence id="DBMI.pac188.s69" origId="s69" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg Without Ritonavir: ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution."/>
	<sentence id="DBMI.pac188.s70" origId="s70" text="In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs."/>
	<sentence id="DBMI.pac188.s71" origId="s71" text="Clinical Studies of Treatment-Experienced Patients: In studies of treatment-experienced patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs."/>
	<sentence id="DBMI.pac188.s72" origId="s72" text="The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir and an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T."/>
	<sentence id="DBMI.pac188.s73" origId="s73" text="Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates."/>
	<sentence id="DBMI.pac188.s74" origId="s74" text="Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution."/>
	<sentence id="DBMI.pac188.s75" origId="s75" text="The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term treatment."/>
	<sentence id="DBMI.pac188.s76" origId="s76" text="Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance."/>
	<sentence id="DBMI.pac188.s77" origId="s77" text="Cross-Resistance\n\nCross-resistance among PIs has been observed."/>
	<sentence id="DBMI.pac188.s78" origId="s78" text="Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV."/>
	<sentence id="DBMI.pac188.s79" origId="s79" text="Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to ATV."/>
	<sentence id="DBMI.pac188.s80" origId="s80" text="Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV."/>
	<sentence id="DBMI.pac188.s81" origId="s81" text="Isolates resistant to ATV were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir."/>
	<sentence id="DBMI.pac188.s82" origId="s82" text="In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs."/>
	<sentence id="DBMI.pac188.s83" origId="s83" text="Baseline Genotype/Phenotype and Virologic Outcome Analyses\n\nGenotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation of ATV/RTV therapy."/>
	<sentence id="DBMI.pac188.s84" origId="s84" text="An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045 is shown in Table 19."/>
	<sentence id="DBMI.pac188.s85" origId="s85" text="Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced patients."/>
	<sentence id="DBMI.pac188.s86" origId="s86" text="In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to patients with 12 PI substitutions, including one of these substitutions."/>
	<sentence id="DBMI.pac188.s87" origId="s87" text="The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 20)."/>
	<sentence id="DBMI.pac188.s88" origId="s88" text="The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen."/>
	<sentence id="DBMI.pac188.s89" origId="s89" text="Additional data are needed to determine clinically relevant break points for REYATAZ."/>
	<sentencespan id="DBMI.pac188.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nAtazanavir is an antiviral drug [see Clinical Pharmacology (12.4)]. 12.2 Pharmacodynamics\n\nEffects on Electrocardiogram\n\nConcentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir. In a placebo-controlled study (AI424-076), the mean (SD) maximum change in PR interval from the predose value was 24 (15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (11) msec following dosing with placebo (n=67)."/>
	<sentencespan id="DBMI.pac188.sp1" origId="sp1" text="The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram. [See Warnings and Precautions (5.2).]"/>
	<sentencespan id="DBMI.pac188.sp2" origId="sp2" text="Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects. Oral doses of 400 mg and 800 mg were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericias correction). In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens."/>
	<sentencespan id="DBMI.pac188.sp3" origId="sp3" text="No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval &gt;500 msec. [See Warnings and Precautions (5.2).] In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.">
		<entity charOffset="1469-1480" id="DBMI.pac188.sp3.e0" origId="sp3.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1502-1512" id="DBMI.pac188.sp3.e1" origId="sp3.e1" text="diltiazem " type="Active ingredient"/>
		<pair e1="DBMI.pac188.sp3.e0" e2="DBMI.pac188.sp3.e1" id="DBMI.pac188.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diltiazem " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.sp3.e1" e2="DBMI.pac188.sp3.e0" id="DBMI.pac188.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac188.sp4" origId="sp4" text="In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. [See Warnings and Precautions (5.2).] 12.3 Pharmacokinetics\n\nThe pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with ritonavir 100 mg once daily (see Table 14).">
		<entity charOffset="1694-1705" id="DBMI.pac188.sp4.e0" origId="sp4.e0" text="atazanavir " type="Active ingredient"/>
		<entity charOffset="1727-1736" id="DBMI.pac188.sp4.e1" origId="sp4.e1" text="atenolol " type="Active ingredient"/>
		<pair e1="DBMI.pac188.sp4.e0" e2="DBMI.pac188.sp4.e1" id="DBMI.pac188.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atenolol " precipitant="atazanavir "/>
		<pair e1="DBMI.pac188.sp4.e1" e2="DBMI.pac188.sp4.e0" id="DBMI.pac188.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac188.sp5" origId="sp5" text="Figure 1 displays the mean plasma concentrations of atazanavir at steady state after REYATAZ 400 mg once daily (as two 200-mg capsules) with a light meal and after REYATAZ 300 mg (as two 150-mg capsules) with ritonavir 100 mg once daily with a light meal in HIV-infected adult patients. Absorption\n\nAtazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200800 mg once daily."/>
	<sentencespan id="DBMI.pac188.sp6" origId="sp6" text="Steady-state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold. Food Effect\n\nAdministration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability. Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp7" origId="sp7" text="Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state. Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state. Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp8" origId="sp8" text="Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours. Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state."/>
	<sentencespan id="DBMI.pac188.sp9" origId="sp9" text="Distribution\n\nAtazanavir is 86% bound to human serum proteins and protein binding is independent of concentration. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively). In a multiple-dose study in HIV-infected patients dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen."/>
	<sentencespan id="DBMI.pac188.sp10" origId="sp10" text="The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42. Metabolism\n\nAtazanavir is extensively metabolized in humans. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation."/>
	<sentencespan id="DBMI.pac188.sp11" origId="sp11" text="Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. Two minor metabolites of atazanavir in plasma have been characterized. Neither metabolite demonstrated in vitro antiviral activity."/>
	<sentencespan id="DBMI.pac188.sp12" origId="sp12" text="In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A. Elimination\n\nFollowing a single 400-mg dose of 14C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively."/>
	<sentencespan id="DBMI.pac188.sp13" origId="sp13" text="The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal. Special Populations\n\nPediatrics\n\nThe pharmacokinetic data from pediatric patients receiving REYATAZ Capsules with ritonavir based on body surface area are presented in Table 15. Drug Interaction Data\n\nAtazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 M. Atazanavir is also a direct inhibitor for UGT1A1 (Ki=1.9 M) and CYP2C8 (Ki=2.1 M)."/>
	<sentencespan id="DBMI.pac188.sp14" origId="sp14" text="Atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A. In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous 6-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced. Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for pharmacokinetic interactions."/>
	<sentencespan id="DBMI.pac188.sp15" origId="sp15" text="The effects of coadministration of REYATAZ on the AUC, Cmax, and Cmin are summarized in Tables 16 and 17. For information regarding clinical recommendations, see Drug Interactions (7). 12.4 Microbiology\n\nMechanism of Action\n\nAtazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI)."/>
	<sentencespan id="DBMI.pac188.sp16" origId="sp16" text="The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Antiviral Activity in Cell Culture\n\nAtazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC50) in the absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells. ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture."/>
	<sentencespan id="DBMI.pac188.sp17" origId="sp17" text="ATV has variable activity against HIV-2 isolates (1.9 to 32 nM), with EC50 values above the EC50 values of failure isolates. Two-drug combination antiviral activity studies with ATV showed no antagonism in cell culture with NNRTIs (delavirdine, efavirenz, and nevirapine), PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of viral hepatitis, adefovir and ribavirin, without enhanced cytotoxicity. Resistance\n\nIn Cell Culture: HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV)."/>
	<sentencespan id="DBMI.pac188.sp18" origId="sp18" text="HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral strains were selected in cell culture by 5 months. The substitutions in these HIV-1 viruses that contributed to ATV resistance include I50L, N88S, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following drug selection."/>
	<sentencespan id="DBMI.pac188.sp19" origId="sp19" text="Recombinant viruses containing the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively, and did not appear to be cross-resistant. Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients."/>
	<sentencespan id="DBMI.pac188.sp20" origId="sp20" text="A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 18. Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg With Ritonavir 100 mg: In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA 400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment. In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M."/>
	<sentencespan id="DBMI.pac188.sp21" origId="sp21" text="The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance. Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline. The 150L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibiity from baseline."/>
	<sentencespan id="DBMI.pac188.sp22" origId="sp22" text="Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance. In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M. Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance."/>
	<sentencespan id="DBMI.pac188.sp23" origId="sp23" text="Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg Without Ritonavir: ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution. In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs. Clinical Studies of Treatment-Experienced Patients: In studies of treatment-experienced patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs."/>
	<sentencespan id="DBMI.pac188.sp24" origId="sp24" text="The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir and an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T. Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates. Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution."/>
	<sentencespan id="DBMI.pac188.sp25" origId="sp25" text="The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term treatment. Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance. Cross-Resistance\n\nCross-resistance among PIs has been observed."/>
	<sentencespan id="DBMI.pac188.sp26" origId="sp26" text="Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV. Greater than 90% of the isolates with substitutions that included I84V or G48V were resistant to ATV. Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV."/>
	<sentencespan id="DBMI.pac188.sp27" origId="sp27" text="Isolates resistant to ATV were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, and 80% resistant to amprenavir. In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI resistance-associated substitution were also cross-resistant to other PIs. Baseline Genotype/Phenotype and Virologic Outcome Analyses\n\nGenotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation of ATV/RTV therapy."/>
	<sentencespan id="DBMI.pac188.sp28" origId="sp28" text="An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045 is shown in Table 19. Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced patients. In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71, 77, 82, or 90, were present compared to patients with 12 PI substitutions, including one of these substitutions."/>
	<sentencespan id="DBMI.pac188.sp29" origId="sp29" text="The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 20). The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen. Additional data are needed to determine clinically relevant break points for REYATAZ."/>
</document>
